Consilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum93321Research ArticleSovremennaya antigipertenzivnaya terapiya:mesto β-adrenoblokatora bisoprololaManeshinaO. A-ErofeevaS. B-BelousovYu. B-SokolovA. V-TishchenkovaI. F-15012011131283328122021Copyright © 2011, Consilium Medicum2011[Кобалава Ж.Д., Гудкова К.М. Секреты артериальной гипертонии: ответы на ваши вопросы. М., 2004; с. 172.][Psaty B.M., Heckbert S.R., Koepsell T.D. et al. The risk of myocardial infarction Pahor M, Guralnik J.M., Corti M.C. et al. Long - term survival and uses of antihypertensive medications in older persons. J Am Geriatr Soc 1995; 49: 1191–7. associated with antihypertensive drug therapies. JAMA 1995; 274: 620–5.][Pahor M, Guralnik J.M., Corti M.C. et al. Long - term survival and uses of antihypertensive medications in older persons. J Am Geriatr Soc 1995; 49: 1191–7.][Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2133.][Brown M.J. The causes of essencial hypertension. Br J Clin Pharm 1996; 42: 21–7.][O\'Shaughnessy K.M., Dickerson C, Thurston D et al. The gain - of - fuction G389R variant of the beta - 1 - adrenoreceptor does not influence blood pressure or heart rate responce to beta - blockade in hypertensive subjects. Clin Sci (Lond) 2000; 99 (3); 231–2.][Van den Meiracker A.H., Man A.J., van Eck H.J. et al. Hemodynamic and hormanal adaptations to beta - adrenoreceptor blockade. A 24-hour study of acebutolol, atenolo. pindolol, and propranolol in hypertensive patients. Circulation 1988; 78; 957–68.][Carlsberg B, Samuelsson O, Lindholm L.H. Atenolol in hypertension: is it a wise choice? Lancet 2004; 364: 1684–9.][Lindholm L.H., Carlsberg B, Samuelsson Should b - blockers first choice in the treatment of primary hypertension? A meta - analysis. Lancet 2005; 366: 1545–53.][Кобалава Ж.Д., Котовская Ю.В. Артериальная гипертония: ключи к диагностике и лечению. М., 2007; с. 198.][Jacob S et al. Am О Hypertens 1998; 11: 1258–65.][Elliott W.J., Meyer P.M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta - analysis. Lancet 2007; 369: 201–7.][Mancia G, Grassi G, Zanchetti A. New - onset diabetes andantihypertensive drugs. J Hypertens 2006; 24: 3–10.][Zanchetti A, Hennig M, Baurecht H et al. Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima - media thickness. J Hypertens 2007; 25: 2463–70.][Barr E.L., Zimmet P.Z., Welborn T.A. et al. Risk of cardiovascular and all - cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes. Obesity and Lifestyle Study (AusDiab). Circulation 2007; 116: 151–7.][Mozaffarian D, Marfisi R, Levantesi G et al. Incidence of new - onset diabetes and impaired fasting glucose in patients with recent myocardial infarction and the effect of clinical and lifestyle risk factors. Lancet 2007; 370: 667–75.][Alderman M.H., Cohen H, Madhavan S. Diabetes and cardiovascular events in hypertensive patients. Hypertension 1999; 33: 1130–4.][Gress T.W., Nieto J, Shahar У et al. N Eng J Med 2000; 342: 905–12.][Dahlӧf B et al. ASCOT Investigators. Lancet 2005; 366: 895.][Lindholm L.H. et al. Lancet 2002; 359: 1004–10.][Lindholm L.H., Persson M, Alaupovic F et al. Hypertens 2003; 21 (8): 1563–74.][Bakris G.L. et al. JAMA 2004; 292: 2227–36.][Benetos et al. J Hypertens 2002.]